NASDAQ : PGNY

Progyny, Inc.

$31.19 USD

$0.49 (1.6%)

Volume
644.56K
Average Volume
1.49M
Market Capitalization
$2.44B
P/E Ratio
38.51
Dividend Yield
0.00%
Price Target
$35.00
Year High
$33.07
Year Low
$16.10
Day High
—
Day Low
—
Payout Ratio
$0.00
Current Ratio
$2.13
Company Overview

NASDAQ

Pete Anevski

Medical - Healthcare Information Services

Healthcare

PGNY

856

US

USD

https://www.progyny.com

212 888 3124

74340E103

0001551306

Liquidity Metrics

0.06

2.13

2.13

0.56

0.00

Sales & Valuation

$1.29B

1.89

5.74

13.25

2.28

Profitability

$0.65

$58.52M

5.23%

8.18%

13.34%

9.69%

P/E Metrics

38.51

1.10

1.10

Analyst Price Target & Rating

$35.00

$40.00

$27.00

Buy

4/5

20 Analysts

-10.89%

Financial Health Scores

8.83

6/9

$265.81M

$698.34M

$258.99M

$105.78M

Key Metrics (TTM)

$2.34B

1.81

21.04

2.13

13.34%

13.23%

2.68%

7.55%

$10.11

16 days

Company Executives
Name Title
Allison Swartz Executive Vice President, General Counsel & Secretary
Mark S. Livingston Chief Financial Officer
Peter Anevski Chief Executive Officer & Director
Cassandra Pratt Chief Human Resources Officer
Melissa Cummings Chief Operating Officer
James Hart Vice President of Investor Relations
Risa Fisher Chief Marketing Officer
Geoffrey Clapp Chief Product Officer
David J. Schlanger Executive Chairman
Steven Leist Chief Technology Officer
Julie Stadlbauer Chief Business Development Officer
Poll Results

No votes yet today — be the first to share your view!

About Progyny, Inc. (NASDAQ:PGNY) Stock

Progyny, Inc. functions as a benefits management corporation, dedicated to providing specialized solutions for fertility and broader family-building initiatives to employers throughout the United States. Its core fertility offering is characterized by a distinctive benefits plan architecture, paired with personalized, white-glove member support services and access to a meticulously chosen network of top-tier fertility specialists. Additionally, the company presents Progyny Rx, an all-encompassing pharmacy benefits solution that ensures its members can readily acquire the essential medications for their treatments. Moreover, Progyny facilitates employer-sponsored reimbursement programs to support surrogacy and adoption journeys. The company, which was established in 2008 and has its main of ... fices in New York City, previously operated as Auxogyn, Inc. before adopting the Progyny, Inc. moniker in 2015.

Progyny, Inc. Announces Details for Its Second Quarter 2026 Results Report

2026-07-23 15:30:00

NEW YORK, July 23, 2026 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a global leader in women's health and family building solutions, will report its financial results for the quarterly period ended June 30, 2026 after the close of the market on Thursday, August 6, 2026.

Progyny COO Cummings Sells 3,437 Shares for $109,000 -- Here's What That Means for Investors

2026-07-19 05:41:01

Melissa B. Cummings disposed of 3,437 shares for a total value of ~$109,000 on July 14, 2026. The transaction reduced the insider's direct equity holdings by 5%.

5 Top Stocks With Relative Price Strength to Buy Right Now

2026-07-17 10:30:34

JBHT, PGNY, BSET, VSXY and PARR stand out for relative price strength, positive estimate revisions and solid fundamentals amid market uncertainty.

Progyny, Inc. (PGNY) Hit a 52 Week High, Can the Run Continue?

2026-07-14 10:15:24

Progyny (PGNY) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Why Progyny (PGNY) Might be Well Poised for a Surge

2026-07-09 13:20:11

Progyny (PGNY) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Are You Looking for a Top Momentum Pick? Why Progyny (PGNY) is a Great Choice

2026-07-09 13:01:13

Does Progyny (PGNY) have what it takes to be a top stock pick for momentum investors? Let's find out.

What Makes Progyny (PGNY) a New Strong Buy Stock

2026-07-09 13:01:09

Progyny (PGNY) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

What Does the Sale of Progyny Shares by the CFO Mean for Investors?

2026-06-25 13:05:01

CFO Mark Livingston sold 8,275 shares for a transaction value of ~$211,000 on May 20, 2026. This represented 9.47% of Livingston's direct holdings, reducing his direct position to 79,063 shares.

Frequently Asked Questions

What is the current Progyny, Inc. (PGNY) stock price?

Progyny, Inc.(NASDAQ:PGNY) stock price is $31.19 in the last trading session. During the trading session, PGNY stock reached the peak price of $33.065 while $16.1 was the lowest point it dropped to. The percentage change in PGNY stock occurred in the recent session was 1.6% while the dollar amount for the price change in PGNY stock was $0.49.

PGNY's industry and sector of operation?

The NASDAQ listed PGNY is part of Medical - Healthcare Information Services industry that operates in the broader Healthcare sector.

Who are the executives of PGNY?

Allison Swartz | Executive Vice President, General Counsel & Secretary
Mark S. Livingston | Chief Financial Officer
Peter Anevski | Chief Executive Officer & Director
Cassandra Pratt | Chief Human Resources Officer
Melissa Cummings | Chief Operating Officer

How many employees does PGNY have?

Number of PGNY employees currently stands at 856. PGNY operates from 1359 Broadway, New York City, NY 10018, US.

Link for PGNY official website?

Official Website of PGNY is: https://www.progyny.com

How do I contact PGNY?

PGNY could be contacted at phone #212 888 3124 and can also be accessed through its website. PGNY operates from 1359 Broadway, New York City, NY 10018, US.

How many shares of PGNY are traded daily?

The average number of PGNY shares traded daily for last 3 months was 1.49M.

What is the market cap of PGNY currently?

The market value of PGNY currently stands at $2.44B with its latest stock price at $31.19